Börse Express – Roche receives approval for Alecensa in China for the treatment of lung cancer

The pharmaceutical company Roche has one
Achieved success in China. The local health authority (CNDA) has departed
the Alecensa medication for the treatment of ALK-positive, not
small cell lung cancer also, such as the Swiss company on
Monday announced.

The decision of the CNDA follows an accelerated pace
Admission procedure, the so-called "priority review". corresponding
Approvals have already been granted by the European Healthcare Authority EMA
and the FDA issued in the US./cf/AWP/tav

    ISIN US7170811035 CH0012032048

AXC0038 2018-08-20 / 07: 40

Copyright dpa-AFX Business News GmbH. All rights reserved. Redistribution, republishing or permanent storage without the express prior permission of dpa-AFX is not permitted.

Source link

Leave a Reply